EA202091455A1 - STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING EVEROLIMUS - Google Patents

STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING EVEROLIMUS

Info

Publication number
EA202091455A1
EA202091455A1 EA202091455A EA202091455A EA202091455A1 EA 202091455 A1 EA202091455 A1 EA 202091455A1 EA 202091455 A EA202091455 A EA 202091455A EA 202091455 A EA202091455 A EA 202091455A EA 202091455 A1 EA202091455 A1 EA 202091455A1
Authority
EA
Eurasian Patent Office
Prior art keywords
everolimus
pharmaceutical composition
composition containing
granules
stabilized pharmaceutical
Prior art date
Application number
EA202091455A
Other languages
Russian (ru)
Inventor
Киунг Хее Хан
Мин Соо Ким
Шин Юнг Парк
Йонг Лае Лим
Original Assignee
Чонг Кун Данг Фармасьютикал Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чонг Кун Данг Фармасьютикал Корп. filed Critical Чонг Кун Данг Фармасьютикал Корп.
Publication of EA202091455A1 publication Critical patent/EA202091455A1/en

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41A—FUNCTIONAL FEATURES OR DETAILS COMMON TO BOTH SMALLARMS AND ORDNANCE, e.g. CANNONS; MOUNTINGS FOR SMALLARMS OR ORDNANCE
    • F41A17/00—Safety arrangements, e.g. safeties
    • F41A17/42—Safeties for locking the breech-block or bolt in a safety position
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Настоящее изобретение относится к стабилизированному фармацевтическому составу, содержащему эверолимус. В частности, настоящее изобретение относится к фармацевтическому составу, содержащему гранулы, содержащие эверолимус в качестве активного ингредиента и бутилгидрокситолуол в качестве антиоксиданта. Кроме того, настоящее изобретение относится к способу получения фармацевтического состава, содержащего эверолимус в качестве активного ингредиента и бутилгидрокситолуол в качестве антиоксиданта, включающему стадии: растворения эверолимуса, бутилгидрокситолуола и связующего(их) и получение смеси; получения гранул из смеси и добавления связывающего вещества в гранулы с получением смеси гранул.The present invention relates to a stabilized pharmaceutical formulation containing everolimus. In particular, the present invention relates to a pharmaceutical formulation containing granules containing everolimus as an active ingredient and butylhydroxytoluene as an antioxidant. In addition, the present invention relates to a method for preparing a pharmaceutical composition containing everolimus as an active ingredient and butylhydroxytoluene as an antioxidant, comprising the steps of: dissolving everolimus, butylhydroxytoluene and a binder (s) and preparing a mixture; obtaining granules from the mixture; and adding a binder to the granules to obtain a mixture of granules.

EA202091455A 2018-01-12 2019-01-07 STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING EVEROLIMUS EA202091455A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180004458A KR102051806B1 (en) 2018-01-12 2018-01-12 Stabilized pharmaceutical formulation comprising Everolimus
PCT/KR2019/000204 WO2019139313A1 (en) 2018-01-12 2019-01-07 Stabilized pharmaceutical formulation comprising everolimus

Publications (1)

Publication Number Publication Date
EA202091455A1 true EA202091455A1 (en) 2020-10-05

Family

ID=67219083

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091455A EA202091455A1 (en) 2018-01-12 2019-01-07 STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING EVEROLIMUS

Country Status (7)

Country Link
JP (1) JP7218372B2 (en)
KR (1) KR102051806B1 (en)
CN (1) CN111565714B (en)
BR (1) BR112020014292A2 (en)
EA (1) EA202091455A1 (en)
MX (1) MX2020007434A (en)
WO (1) WO2019139313A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111388455B (en) * 2020-04-09 2022-09-02 沈阳药科大学 Everolimus oral film and preparation method thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US20100266590A1 (en) * 2006-08-02 2010-10-21 Demetri George D Combination therapy
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
PT2365802T (en) * 2008-11-11 2017-11-14 Univ Texas Microcapsules of rapamycin and use for treating cancer
SG11201400730VA (en) * 2011-10-06 2014-06-27 Novartis Ag Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
KR20140032586A (en) * 2012-09-06 2014-03-17 한국원자력의학원 A pharmaceutical composition for radiation therapy of egfr-tki-resistant lung cancer caused by pten function deficiency
TW201503912A (en) * 2013-03-19 2015-02-01 Novartis Ag Pharmaceutical compositions comprising everolimus
MX367121B (en) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Stable solid composition of immunosuppressants.
KR20150138104A (en) * 2014-05-30 2015-12-09 동아에스티 주식회사 Pharmaceutical preperation containing Bepotastine and Glyceryl Behenate
CN104398483B (en) * 2014-11-05 2018-01-26 上海医药集团青岛国风药业股份有限公司 A kind of olmesartan medoxomil tablet and its preparation technology
CN105106145A (en) * 2015-08-27 2015-12-02 济川药业集团有限公司 Everolimus tablet and preparation method thereof
WO2017038925A1 (en) * 2015-09-03 2017-03-09 日本化薬株式会社 Pharmaceutical composition containing rapamycin or derivative thereof
JP2018111662A (en) * 2017-01-12 2018-07-19 ニプロ株式会社 Everolimus pharmaceutical preparation

Also Published As

Publication number Publication date
KR20190086212A (en) 2019-07-22
CN111565714A (en) 2020-08-21
JP7218372B2 (en) 2023-02-06
KR102051806B1 (en) 2019-12-04
CN111565714B (en) 2022-05-17
BR112020014292A2 (en) 2020-12-08
MX2020007434A (en) 2022-04-27
WO2019139313A1 (en) 2019-07-18
JP2021510374A (en) 2021-04-22

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201790389A1 (en) PYRROPYRIMIDINE COMPOUNDS USED AS AN AGLIST TLR7
PH12018502516B1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CL2018002920A1 (en) New pyrazolopyrimidine derivatives
EA201891099A1 (en) 7- (TIAZOL-5-IL) Pyrrolopyrimide as an agonist of the TLR7 receptor
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201790306A1 (en) 2- (MORFOLIN-4-IL) -1,7-NAFTYRIDINES
EA201892734A1 (en) AZABENZIMIDAZOLE DERIVATIVES AS AN INTEGRATOR OF pI3K BETA INHIBITORS
EA201792421A1 (en) AMIDO-SUBSTITUTED DERIVATIVES OF CYCLOGEXANE
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MX367914B (en) SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a</ i>][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS.
PH12020550608A1 (en) Pyrrole derivatives as acc inhibitors
MX2021006969A (en) Peptide binder.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX2019012454A (en) Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin- 2-yl)-1h-pyrazol-5-ol hydrochloride.
EP4327880A3 (en) Solid state form of ribociclib succinate
CU20200008A7 (en) SUBSTITUTE DIHYDROOXADIAZINONE COMPOUNDS USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES, METHODS FOR PREPARING SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU2017262586A1 (en) Improved drug formulations
EA201890906A1 (en) DERIVATIVES OF CHINOXALINE AND PYRIDOPYRASINE AS PI3Kβ INHIBITORS
MX2019008865A (en) Solid preparation comprising tofogliflozin and method for producing same.
MX2017008074A (en) IMIDAZOPYRIDAZINE DERIVATIVES AS PI3Kß INHIBITORS.
EA202090978A1 (en) NEW MACROCYCLIC DERIVATIVES, THE METHOD OF THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS
EA202091455A1 (en) STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING EVEROLIMUS
WO2016005995A3 (en) Glycol free stable liquid compositions of bendamustine
EA202191515A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING APIXABAN